Location History:
- La Habana, CU (2015)
- Havana, CU (2019)
Company Filing History:
1 out of 70 
1 out of 15 Years Active: 2015-2019
Title: Leonor Margarita Navea Leyva: Advancing HIV Replication Inhibition through Cytoskeletal Alteration
Introduction:
Leonor Margarita Navea Leyva, a talented inventor hailing from Havana, Cuba, has made significant contributions to the field of biomedical sciences. With a strong focus on inhibiting HIV replication in mammal and human cells, Leyva has developed innovative methods that involve the alteration of the cytoskeleton. This article explores his latest patents, career highlights, notable collaborations, and the impact of his work.
Latest Patents:
Leonor Margarita Navea Leyva has secured two pioneering patents, both centered around inhibiting HIV replication through cytoskeletal alteration. The patents primarily focus on modulating or altering the proteins within the intermediate cytoskeletal filaments, namely vimentin and/or keratin-10. By intervening in the structure of these proteins, Leyva's inventions effectively hinder HIV replication in both human and mammalian cells. The patents propose several agents, including peptides, interfering RNA, and lipidic compounds, that contribute to the negative modulation or alteration of the cytoskeleton. Overall, these inventions aim to prevent and treat HIV infection by disrupting the cytoskeleton/filament structure of cells.
Career Highlights:
Leonor Margarita Navea Leyva's expertise and dedication have led him to work in esteemed institutions at the forefront of genetic engineering and biotechnology. Notably, Leyva has been associated with the Centro de Ingeniería Genética y Biotecnología (Center for Genetic Engineering and Biotechnology), a prestigious research institution situated in Havana, Cuba. During his tenure, Leyva has demonstrated immense proficiency in his field, as evidenced by his exceptional patent innovations surrounding HIV replication inhibition.
Collaborations:
Leyva has had the privilege of working alongside fellow skilled individuals in the field of biomedical research. Notably, his collaborations include Celia Berta Fernandez Ortega and Dionne Casillas Casanova. Their combined expertise and diverse perspectives have likely aided in propelling Leyva's inventive endeavors towards groundbreaking solutions in inhibiting HIV replication.
Conclusion:
Leonor Margarita Navea Leyva's pioneering research in inhibiting HIV replication by altering the cytoskeleton demonstrates his commitment to developing innovative solutions in the biomedical field. His patents highlighting the modulation of proteins vimentin and keratin-10 as well as the introduction of various agents underscore his potential contributions to preventing and treating HIV infections. Leyva's association with the Centro de Ingeniería Genética y Biotecnología and collaboration with esteemed colleagues further solidify his impact in the field. Through these groundbreaking advancements, Leyva's work holds the potential to significantly impact the ongoing fight against HIV/AIDS and bring hope for improved treatments and prevention strategies.